home / stock / qlgn / qlgn news

QLGN News and Press, Qualigen Therapeutics Inc. From 03/08/23

Stock Information
Company Name: Qualigen Therapeutics Inc.
Stock Symbol: QLGN
Market: NASDAQ
Website: qualigeninc.com
Menu
QLGN QLGN Quote QLGN Short QLGN News QLGN Articles QLGN Message Board
Get QLGN Alerts

News, Short Squeeze, Breakout and More Instantly...
QLGN - OPK, FRTX and QLGN among pre market gainers

2023-03-08 08:36:27 ET Fresh Tracks Therapeutics ( FRTX ) +83% on announcing positive topline results from single and multiple ascending dose parts of phase 1 study of Oral DYRK1A Inhibitor FRTX-02. Kimball International ( KBAL ) +75% HNI to acquire Kimball i...
QLGN - Data on Potential Biomarker for Qualigen Therapeutics' Lead Program QN-302 Published in Peer-Reviewed Journal Molecules

S100P Gene Expression May Be Marker of Anti-Tumor Activity in Pancreatic Cancer In Vivo Models CARLSBAD, Calif., March 08, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLG...

QLGN - Qualigen Therapeutics Chief Executive Officer Michael Poirier Provides Letter to Stockholders

CARLSBAD, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designatio...

QLGN - Qualigen Therapeutics Initiates Good Laboratory Practice (GLP) Toxicology Studies on QN-302

CARLSBAD, Calif., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designatio...
QLGN - Qualigen Therapeutics Promotes Benedict M. Abugan to Vice President, Head of Diagnostics and Corporate Communications

CARLSBAD, Calif., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designatio...

QLGN - Qualigen stock soars 15% on FDA orphan drug status for pancreatic cancer therapy

Qualigen Therapeutics ( NASDAQ: QLGN ) stock rose ~15% on Tuesday after the company said that the U.S. Food and Drug Administration (FDA) granted orphan drug designation (ODD) to QN-302 to treat pancreatic cancer. "Receiving Orphan Drug Designation for our lead cancer therapeu...

QLGN - Qualigen Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for QN-302, a G-Quadruplex (G4) Transcription Inhibitor for the Intended Indication of Pancreatic Cancer

CARLSBAD, Calif., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designatio...
QLGN - Qualigen Therapeutics Provides Update on Developments at NanoSynex; Significant Progress Reported on Infectious Disease Diagnostic Platform

CARLSBAD, Calif., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designatio...

QLGN - Qualigen Therapeutics regains compliance with Nasdaq minimum bid price rule

Qualigen Therapeutics ( NASDAQ: QLGN ) has received Nasdaq notice, informing the company that it has regained compliance minimum bid price requirement and the matter is now closed. The closing bid price of the company’s common stock having been at least $1.00 per share for ...

QLGN - Qualigen Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule

CARLSBAD, Calif., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designatio...
Previous 10 Next 10